Maintenance treatment with Soliris (eculizumab) every three to six weeks — instead of the standard two weeks — is…
Articles by Patricia Inácio, PhD
COVID-19 was a strong trigger for relapses of atypical hemolytic uremic syndrome (aHUS) in two brothers who were genetically…
A new mutation in the CD46 gene linked to recurrent atypical hemolytic uremic syndrome (aHUS) was identified in a…
A total of 30 patient advocacy groups working to further understanding and the needs of people living with rare diseases…
Soliris (eculizumab) safely and effectively treated a severe episode of atypical hemolytic uremic syndrome (aHUS) in an adolescent with…
Soliris (eculizumab) safely and effectively treated children with atypical hemolytic uremic syndrome (aHUS) in a real-world setting, according…
A 30-year-old man is thought to have developed atypical hemolytic uremic syndrome (aHUS) after being vaccinated for…
Two newly reported mutations in a complement-related gene appear to have triggered atypical hemolytic uremic syndrome (aHUS) in a…
Plasma exchange and treatment with Soliris (eculizumab) may be used successfully to treat pregnancy-related atypical hemolytic uremic syndrome (aHUS)…
A 57-year old man developed atypical hemolytic uremic syndrome (aHUS) after being bitten by a pit viper belonging to the…